Trial-anchored psychedelic practice guidance

Informed consent and ethics

Obtain written informed consent and ensure the study is conducted under approved ethical oversight. Facilitators must follow human research ethics standards and protect participants throughout the intervention.

Acute psychiatric monitoring

Monitor for dissociation, psychotomimetic symptoms, and mania during the acute psychedelic phase. Repeated assessments were used to track tolerability and emerging adverse effects.

Pre-session clinical assessment

Conduct a full psychiatric and medical screening before dosing to determine eligibility and identify risks. This includes diagnostic evaluation, symptom severity assessment, and review of personal and family history relevant to psychedelic safety.

Psychiatric symptom assessment

Administer and interpret standardized psychiatric rating scales used in the study to evaluate depression, mania, psychosis-related symptoms, and dissociation. This supports both efficacy tracking and safety surveillance.

Knowledge of ayahuasca pharmacology and effects

Understand the basic pharmacology and clinical effects of ayahuasca to inform safe facilitation and interpretation of responses. The source identifies dimethyltryptamine as a 5-HT2A agonist and harmine as a monoamine-oxidase A inhibitor.

Acute psychedelic effect monitoring

Monitor participants closely during the acute effects of ayahuasca for psychoactivity, dissociation, and other mental status changes. Use structured assessments to track symptom intensity and detect emerging complications.

Clinical trial record navigation

Ability to locate and use study-record information within ClinicalTrials.gov. This includes understanding where to find study details and related administrative information.

Protocol and data element awareness

Knowledge of study record management concepts relevant to registration and results reporting. A facilitator or therapist interacting with trial documentation should understand protocol-linked data fields and their definitions.

Study documentation literacy

General competency in interpreting clinical study documentation and administrative guidance. This supports accurate communication with study systems and research staff.

Psychiatric screening and eligibility assessment

The facilitator must assess whether a participant is appropriate for ayahuasca administration by identifying inclusion factors and exclusion risks. This includes confirming recurrent major depressive disorder and screening for conditions that increase risk of adverse psychiatric reactions.

Informed consent and participant education

The therapist/facilitator must provide detailed information about the expected effects and risks of ayahuasca and ensure voluntary, informed participation. Consent should be documented in writing and obtained after adequate explanation.

Symptom rating and clinical monitoring

The facilitator should be able to administer standardized psychiatric scales repeatedly and interpret changes over time. This supports both safety monitoring and outcome assessment.

Informed consent and risk disclosure

The therapist/facilitator must provide clear, comprehensible information about the substance, expected psychological effects, and potential adverse effects before consent. Consent must be voluntary and documented.

Standardized symptom rating administration

The therapist/facilitator must competently administer repeated clinician-rated scales to track depressive, anxious, and manic symptoms over time. Training and clinical experience in these instruments are required.

Pre-session medical screening

The therapist/facilitator must ensure medical suitability before ayahuasca administration by checking for conditions that increase risk. Screening should include physical exam, laboratory testing, and pregnancy assessment when indicated.

Pre-session psychiatric screening

The facilitator must identify appropriate participants through structured psychiatric evaluation before dosing. This includes confirming diagnosis, treatment resistance, and screening for exclusionary psychiatric and medical risks.

Eligibility and risk exclusion judgment

Facilitators need competency in determining when a patient should not receive the intervention. The study excluded multiple psychiatric, medical, and substance-related risks to reduce harm and confounding.

Monitoring acute psychological effects

Facilitators must monitor for acute dissociation, psychosis-like symptoms, and mania during the session. The protocol used repeated standardized assessments to track these effects over time.

Study record management literacy

The therapist/facilitator should understand how study records are structured and managed within the ClinicalTrials.gov framework. This includes awareness of glossary terms and data element definitions used for registration and results reporting.

Clinical trials record interpretation

Understands how to read and extract information from a ClinicalTrials.gov study record. This includes recognizing that the provided source is a study listing rather than a clinical protocol or therapist manual.

Clinical trial registration literacy

Understands the basic structure and purpose of a ClinicalTrials.gov study record. Can locate and interpret study registration information relevant to the intervention context.

Ethical use of trial information

Uses publicly available trial information responsibly and within its intended scope. Respects that registry content is not a substitute for clinical judgment, consent procedures, or study-specific training.

Study record data interpretation

Can extract limited operational information from a study record and distinguish it from clinical or therapeutic guidance. This supports appropriate use of trial documentation in a therapy or facilitation setting.

Safety monitoring during ayahuasca sessions

Facilitators must continuously monitor physical and psychological safety during and after ayahuasca administration. This includes observing distress, checking vital signs, and responding to adverse effects promptly.

Meaning reconstruction therapy delivery

Therapists must competently deliver the 9-session meaning reconstruction protocol for grief, including its event story, back story, and personal story phases. The work is aimed at helping bereaved participants make sense of the loss, revise attachment-related meanings, and reconstruct identity and future orientation.

Psychedelic integration support

Therapists must help participants process and assimilate ayahuasca experiences after the session. Integration follows non-directive, restorative retelling principles to translate acute experiences into narrative and behavioral change.

Presence during altered state

Remain with the patient during the altered state of consciousness after dosing to provide containment, support, and safety monitoring. This is a core facilitation responsibility during the dosing session.

Psychedelic research safety practices

Apply established safety practices specific to psychedelic research throughout treatment. The facilitator must support safe administration, monitoring, and discharge readiness.

Discharge readiness assessment

Assess whether the patient is ready for discharge after dosing using the structured readiness questionnaire. This is a safety gate before the patient leaves the clinic.

Monitoring anxiety and depression outcomes

Able to assess and track changes in depression and anxiety over the course of treatment. This includes using standardized rating scales and interpreting symptom change pre- and post-treatment.

Outcome interpretation in pilot research settings

Understands that findings from a pilot evaluation support feasibility and preliminary effectiveness rather than definitive efficacy. The facilitator should interpret outcomes cautiously and support structured data collection.

Knowledge of ayahuasca and traditional Amazonian medicine

Understands the therapeutic role of ayahuasca as a psychoactive plant brew used ritually in traditional Amazonian medicine. Knowledge of the cultural and medicinal context is necessary to support safe and appropriate facilitation.

Rigorous participant screening

Conduct structured pre-screening and formal screening to identify exclusion criteria and reduce risk before experimental sessions. This includes building rapport, gathering key history, and referring suitable candidates for diagnostic evaluation.

Supportive set-and-setting preparation

Create a controlled, comfortable, and low-stimulus environment that supports psychological safety and reduces preventable distress. This includes anticipating both common and severe adverse scenarios before administration.

Therapeutic presence and communication

Maintain a calm, nonjudgmental, and non-directive interpersonal stance that supports the participant without shaping the experience. Communication should be simple, respectful, and focused on reassurance and safety.

Continuous physical monitoring

Participants must be continuously monitored to prevent avoidable hazards. The guide explicitly states that participants should never be left alone.

Ayahuasca pharmacology knowledge

Facilitators should understand the pharmacology of ayahuasca, including its composition and how it produces effects. This knowledge supports safer preparation, dosing, and risk explanation.

Risk and contraindication screening

Facilitators must know the risks and contraindications associated with ayahuasca use. They should identify medical and psychological factors that make participation unsafe or require extra caution.